about
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.Molecular classifications of gastric cancers: Novel insights and possible future applications.New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal InjuryHER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy.Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.Determinants of Last-line Treatment in Metastatic Breast Cancer.Immunotherapy for gastric cancers: emerging role and future perspectives.Do platinum salts fit all triple negative breast cancers?Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.Immunotherapy for colorectal cancer: where are we heading?Sarcopenia in gastric cancer: when the loss costs too much.Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.Pattern of metastasis and outcome in patients with breast cancer.Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalationEstimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life NomogramThe IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patientsControversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) surveySecond-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world studyCorrigendum to "Gastric cancer: Translating novels concepts into clinical practice" [Cancer Treatm. Rev. 79C (2019) 101889]Gastric cancer: Translating novels concepts into clinical practiceLactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic BiomarkerBiologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis
P50
Q33364587-58A2AE88-F934-4525-BCEE-0C8DD908E1D6Q33696201-6047E344-7EAF-4BD6-B3BB-2BC8055FC0F2Q33774917-ABDB4C2D-BBE0-4CB4-BBC6-D65362EF30BDQ37708897-BCE8C5E5-25B6-41CF-A25F-3C9CF427D0F0Q38581768-BD066C64-82A2-4B15-BE4F-AAEBCCA752FBQ38599120-04F1C043-405E-43BA-97DA-0CDD291CF260Q38638382-4C7DF8BC-FBE2-49E3-97FC-44E9308393F9Q38738652-86953EF7-C077-4C7E-929E-D7E6E8AB1538Q38876778-F4E2BD62-414D-4CBD-A9CF-163B66567247Q39061328-63D3CCEB-3CB0-499D-9329-679E2C21C40DQ39218636-67C4243D-B094-40EA-A551-D89CB6D53789Q39287062-3B5A8225-C432-4EE4-9A67-01411428604FQ47915753-8FC391B2-7289-49CE-BCA4-DB7C93E3D1F6Q49959389-EE2A933F-B601-4077-9653-19EA728D71C4Q54294135-58681D28-C484-4F90-89ED-F5C471AE3789Q58589965-F654517C-5989-4CB2-AE80-3F92E550EBABQ61054483-1D10CCBB-B1AC-4063-A39A-A275830719E4Q64229230-7BC9AD19-077E-4C06-9366-11A104A65622Q88429383-5ACD652F-3629-40F2-9600-8FA994331C51Q90520295-2FD09D38-226F-4D2A-AD13-43D430DB623EQ91471708-61509287-29BB-40B9-8CD6-7ADEAB4C6E75Q92841305-E8360822-8ADC-4CF1-A2CC-4C8B7F6844B4Q92874952-49D1DB8A-B8A7-4BCB-904F-5C3FE9C9A33DQ93216536-B7017660-FEB0-4406-8ED2-B049F0ACF72F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Valentina Fanotto
@ast
Valentina Fanotto
@en
Valentina Fanotto
@es
Valentina Fanotto
@nl
Valentina Fanotto
@sl
type
label
Valentina Fanotto
@ast
Valentina Fanotto
@en
Valentina Fanotto
@es
Valentina Fanotto
@nl
Valentina Fanotto
@sl
prefLabel
Valentina Fanotto
@ast
Valentina Fanotto
@en
Valentina Fanotto
@es
Valentina Fanotto
@nl
Valentina Fanotto
@sl
P106
P31
P496
0000-0002-9465-5803